Overview

Diverging from traditional neuro-centric treatment paradigms, we focus on activating the peripheral immune system to facilitate brain repair, offering novel treatment pathways. Our lead program employs IBC-Ab002 — a proprietary, investigational fully human anti-PD-L1 — designed to leverage the PD-1/PD-L1 immune checkpoint pathway for Alzheimer’s disease therapy. The scientific foundation for our work is rooted in the groundbreaking research of Professor Michal Schwartz at the Weizmann Institute of Science.